IntelGenx Technologies (IGXT) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
IntelGenx Corp. has announced that their partner, Xiromed LLC, received a Complete Response Letter from the FDA for the ANDA of Buprenorphine Buccal Film, a generic version of the pain management opioid Belbuca. The FDA has requested additional Pharmaceutical Quality information but confirmed no new inspections are needed at IntelGenx’s facility. The company’s CEO expressed commitment to addressing the FDA’s feedback promptly.
For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue